Department and Graduate Institute of Pharmacology, National Defense Medical Center, Taipei 114, Taiwan.
Department of Pharmacy Practice, Tri-Service General Hospital, National Defense Medical Center, Taipei 114, Taiwan.
Molecules. 2020 Sep 7;25(18):4082. doi: 10.3390/molecules25184082.
Mosquito-borne Zika virus (ZIKV) is a Flavivirus that came under intense study from 2014 to 2016 for its well-known ability to cause congenital microcephaly in fetuses and neurological Guillain-Barré disease in adults. Substantial research on screening antiviral agents against ZIKV and preventing ZIKV infection are globally underway, but Food and Drug Administration (FDA)-approved treatments are not available yet. Compounds from Chinese medicinal herbs may offer an opportunity for potential therapies for anti-ZIKV infection. In this study, we evaluated the antiviral efficacy of harringtonine against ZIKV. Harringtonine possessed anti-ZIKV properties against the binding, entry, replication, and release stage through the virus life cycle. In addition, harringtonine have strong virucidal effects in ZIKV and exhibited prophylaxis antiviral ability prior ZIKV infection. The antiviral activity also observed in the treatment against Japanese encephalitis reporter virus (RP9-GFP strain). Overall, this study demonstrated that harringtonine would be a favorable potential candidate for the development of anti-ZIKV infection therapies.
蚊媒传播的 Zika 病毒（ZIKV）是黄病毒属的一种病毒，因能够导致胎儿先天性小头畸形和成人吉兰-巴雷综合征而在 2014 年至 2016 年期间受到广泛关注。目前全球正在进行针对 ZIKV 的筛选抗病毒药物和预防 ZIKV 感染的大量研究，但尚未获得美国食品和药物管理局（FDA）批准的治疗方法。中草药中的化合物可能为抗 ZIKV 感染的潜在治疗方法提供机会。在这项研究中，我们评估了高三尖杉酯碱对 ZIKV 的抗病毒功效。高三尖杉酯碱通过病毒生命周期在结合、进入、复制和释放阶段具有抗 ZIKV 特性。此外，高三尖杉酯碱对 ZIKV 具有很强的病毒杀伤作用，并在 ZIKV 感染前表现出预防抗病毒能力。在针对日本脑炎报告病毒（RP9-GFP 株）的治疗中也观察到了抗病毒活性。总的来说，这项研究表明，高三尖杉酯碱可能是开发抗 ZIKV 感染治疗方法的一个有前途的候选药物。
